Table 2 In vivo experiments on the antitumor effects of EGCG on TNBC: an update

Xenograft mouse model (MDA-MB-231 cells injected into the dorsal subcutaneous tissue of mice)

EGCG GTP

1 mg/0.1 ml/mouse of EGCG in drinking water for 10 weeks;

0,1% GTP for 10

weeks;

EGCG and GTP decreased proliferation and increased apoptosis of tumors of TNBC- bearing mice.

[20]

Xenograft mouse model (MDA-MB-231 cells injected into the dorsal subcutaneous tissue of mice)

EGCG

Pro- EGCG (1)

50 mg/kg Pro- EGCG(1) for 31 days;

50 mg/kg EGCG(1) for 31 days;

Pro-EGCG (1) targeted the tumor cellular proteasome and inhibited the growth of tumors of TNBC-bearing mice.

[28]

Xenograft mouse model (MDA-MB-231 cells injected into the dorsal subcutaneous tissue of mice) injected into the right axilla of mice)

Pro-F- EGCG2 (Pro-F2)

Pro-F- EGCG4 (Pro-F4)

Pro- EGCG (1)

50 mg/kg by s.c. injection daily for 31 days, Pro-F2;

50 mg/kg by s.c. injection daily for 31 days, Pro-F4;

50 mg/kg by s.c. injection daily for 31 days, Pro-EGCG (1)

Pro-F2 and Pro-F4 induced proteasome inhibition and apoptosis induction and similar to Pro-EGCG (1), inhibited the growth of tumors of TNBC-bearing mice.

[29]